NASDAQ:BLTE Belite Bio - BLTE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. $27.01 +0.13 (+0.48%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$27.00▼$28.0050-Day Range$25.61▼$33.5052-Week Range$8.80▼$44.70Volume17,109 shsAverage Volume13,908 shsMarket Capitalization$672.55 millionP/E RatioN/ADividend YieldN/APrice Target$57.50 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Belite Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.9% Upside$57.50 Price TargetShort InterestHealthy0.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector199th out of 1,005 stocksPharmaceutical Preparations Industry83rd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.50, Belite Bio has a forecasted upside of 112.9% from its current price of $27.01.Amount of Analyst CoverageBelite Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently increased by 1.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 2.7 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Belite Bio this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.46% of the stock of Belite Bio is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Belite Bio (NASDAQ:BLTE) StockBelite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.Read More Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comBelite Bio (NASDAQ:BLTE) Sees Large Volume IncreaseJanuary 25, 2023 | wsj.comBelite Bio Inc. ADRMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.October 20, 2022 | finance.yahoo.comBelite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim DataOctober 1, 2022 | finance.yahoo.comBelite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022September 18, 2022 | seekingalpha.comBelite Bio receives approval of begin LBS-008 phase 3 trial in ChinaSeptember 16, 2022 | finance.yahoo.comBelite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in ChinaAugust 23, 2022 | seekingalpha.comBelite Bio adds 15% as pivotal trial for lead asset starts in U.S.March 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.August 22, 2022 | markets.businessinsider.comBelite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease StudyAugust 13, 2022 | seekingalpha.comBelite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call TranscriptAugust 3, 2022 | nasdaq.comBelite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth PlansAugust 1, 2022 | finance.yahoo.com'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This AnalystAugust 1, 2022 | finance.yahoo.comBelite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial ResultsJuly 30, 2022 | finance.yahoo.comWe're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash WiselyJuly 19, 2022 | markets.businessinsider.comBelite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease StudyJuly 19, 2022 | finance.yahoo.comBelite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt DiseaseJuly 3, 2022 | benzinga.comBelite Bio (NASDAQ:BLTE), Analyst Ratings, Price Targets, PredictionsJuly 1, 2022 | seekingalpha.comHot Stocks: META dips on curtailed hiring; PCT dips on CEO departure; ACCD earnings; BLTE gets Buy ratingJuly 1, 2022 | seekingalpha.comBelite Bio initiated with a Buy at BenchmarkJune 17, 2022 | seekingalpha.comEvoke, Zynerba top healthcare gainers; while 180 Life, Belite Bio lead losers' packJune 14, 2022 | morningstar.comBelite Bio Inc ADR - Stock Quote BLTEJune 13, 2022 | seekingalpha.comBelite Bio jumps 13%, now trading 247% above IPO priceMay 21, 2022 | finanznachrichten.deBelite Bio, Inc: Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public OfferingMay 15, 2022 | investing.comBelite Bio Inc ADR (BLTE)May 9, 2022 | finance.yahoo.comBelite Bio Receives FDA Fast Track Designation For LBS-008May 9, 2022 | finance.yahoo.comBelite Bio Announces Closing of $36 Million Initial Public OfferingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Company Calendar Today3/26/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$57.50 High Stock Price Forecast$58.00 Low Stock Price Forecast$57.00 Forecasted Upside/Downside+112.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio35.01 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares24,900,000Free Float21,590,000Market Cap$672.55 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Ms. Ching-Chen Chiu M.Sc. (Age 53)VP of Clinical Operations Key CompetitorsIDEAYA BiosciencesNASDAQ:IDYAArcutis BiotherapeuticsNASDAQ:ARQTDyne TherapeuticsNASDAQ:DYNCalliditas Therapeutics AB (publ)NASDAQ:CALTIGM BiosciencesNASDAQ:IGMSView All CompetitorsInstitutional OwnershipAlps Advisors Inc.Bought 16,087 shares on 2/15/2023Ownership: 0.065%Morgan StanleySold 16,308 shares on 2/15/2023Ownership: 0.008%Atria Wealth Solutions Inc.Bought 757,560 shares on 2/13/2023Ownership: 3.264%UBS Group AGBought 4,217 shares on 2/8/2023Ownership: 0.017%View All Institutional Transactions BLTE Stock - Frequently Asked Questions Should I buy or sell Belite Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks. What is Belite Bio's stock price forecast for 2023? 2 equities research analysts have issued 12 month target prices for Belite Bio's shares. Their BLTE share price forecasts range from $57.00 to $58.00. On average, they expect the company's stock price to reach $57.50 in the next year. This suggests a possible upside of 112.9% from the stock's current price. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts. How have BLTE shares performed in 2023? Belite Bio's stock was trading at $30.1450 on January 1st, 2023. Since then, BLTE shares have decreased by 10.4% and is now trading at $27.01. View the best growth stocks for 2023 here. When is Belite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our BLTE earnings forecast. What ETF holds Belite Bio's stock ? ALPS Medical Breakthroughs ETF holds 16,217 shares of BLTE stock, representing 0.49% of its portfolio. When did Belite Bio IPO? (BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share. What is Belite Bio's stock symbol? Belite Bio trades on the NASDAQ under the ticker symbol "BLTE." Who are Belite Bio's major shareholders? Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Atria Wealth Solutions Inc. (3.26%), Alps Advisors Inc. (0.06%), UBS Group AG (0.02%) and Morgan Stanley (0.01%). How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Belite Bio's stock price today? One share of BLTE stock can currently be purchased for approximately $27.01. How much money does Belite Bio make? Belite Bio (NASDAQ:BLTE) has a market capitalization of $672.55 million. How can I contact Belite Bio? The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com. This page (NASDAQ:BLTE) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.